New Delhi: Hyderabad-based Bharat Biotech’s pre-submission meeting has been scheduled on June 23 for analysis of the World Health Organisation (WHO)’s Emergency Use Listing (EUL) of its indigenous COVID-19 vaccine Covaxin.
Earlier, final month, Bharat Biotech had knowledgeable that it had submitted 90 per cent of the documentation wanted for WHO’s EUL. The remainder of the paperwork are to be submitted this month.
The External Affairs Ministry is coordinating with Bharat Biotech to safe WHO recognition for the COVID-19 vaccine.
Covaxin is amongst three vaccines at present being administered in India in opposition to the COVID-19 pandemic.
India began the world’s largest vaccination drive on January 16 this yr in a phased method with healthcare staff (HCWs) getting inoculated first. The vaccination of frontline staff (FLWs) began on February 2.
The subsequent section of COVID-19 vaccination commenced from March 1 for these over 60 years of age and for folks aged 45 and above with specified co-morbid circumstances. India launched vaccination for all folks aged greater than 45 from April 1. Phase 3 of the vaccination drive was began on May 1 for the beneficiaries belonging to the age group 18-44.